Avecho Biotechnology Limited
AVEFF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.73M
Close$
$-0.00
164.4% downside
Current Fair Value
164.4% downsideOvervalued by 164.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $16.73 Million |
|---|---|
| Enterprise Value | $10.36 Million |
| Earnings per Share | $0 |
| Beta | 1.13 |
| Outstanding Shares | 3,717,986,625 |
Return
| Return on Equity | -382.39% |
|---|---|
| Return on Assets | -86.72% |
| Return on Invested Capital | -135.86% |
Valuation & Multiples
| P/E Ratio | -9.33 |
|---|---|
| PEG | 33.08 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.89 |
| Enterprise Value to EBIT | -1.11 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Avecho Biotechnology Limited
9 employees
CEO: Paul Gavin
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and Ind...